Browsing Category
Pharma Industry News
4718 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Rapid NOVA-2 enrollment brings LB Pharmaceuticals closer to its first potential FDA filing
LB-102 Phase 3 data move into H1 2027 as LB Pharmaceuticals deploys $150m to expand its psychiatry pipeline ahead of a pivotal test.
Sutacimig Phase 3 path puts Hemab’s $457.5m post-IPO cash base to work
Sutacimig gets an FDA-backed Phase 3 path as Hemab deploys its $457.5m post-IPO cash base. See what the pivotal trial means for growth.
Spero Therapeutics (Nasdaq: SPRO) pivots to immunology after Utebzi approval and $105m financing
Spero Therapeutics uses Utebzi royalties to fund an Innovent immunology pivot. Read how SPRO’s cash runway, CD40L bet and stock discount fit together.
Septerna’s oral hypoparathyroidism strategy gets its first human pharmacokinetic validation
SEP-479’s 3-to-4-day half-life supports once-daily dosing as Septerna targets an oral alternative in hypoparathyroidism. See what comes next.
TNX-103 Phase 3 failure forces Tenax into FDA reset after nearly 90% stock plunge
TNX-103 misses Phase 3 as Tenax shares crash nearly 90%. A 26.3-meter subgroup benefit now drives the company’s FDA rescue strategy.
Glaucoma drug NCX 470 reaches another major market as Nicox’s partner strategy pays off
NCX 470 enters China review as Nicox targets glaucoma royalties across China, the U.S. and Japan. See what the filing means for growth.
Heron Therapeutics (Nasdaq: HRTX) withdraws 2026 guidance as CINVANTI patent ruling reshapes plan
Heron Therapeutics withdrew 2026 guidance and cut $13.5m of Hercules debt after a June Delaware ruling on CINVANTI, with monthly covenants now running through 2027.
Tarsus Pharmaceuticals (NASDAQ: TARS) to add Alkeus in $800m eye pipeline deal
Tarsus lines up an $800m Alkeus deal and a $125m PIPE to enter Stargardt disease, but a 2029 readout and Belite Bio's lead still gate the retina thesis.
Can Ascendis Pharma turn two weekly injections into its next rare-disease growth engine?
Ascendis Pharma’s weekly achondroplasia combination sustains 7.7cm growth as YUVIWEL uptake builds. Read what it means for the franchise.
Platelet biomarker could shape bezisterim Phase 3 strategy after mixed investor response
Bezisterim shows broad Parkinson’s improvements, but BioVie’s stock plunge and cash needs raise doubts. Read the full Phase 2 analysis.